RCS - Incanthera PLC - Proactive Investor Forum Presentation
Incanthera PLC presented at the Proactive Investor Forum on October 9, 2025, focusing on innovative technologies in dermatology and oncology. The recording of the presentation is now available on their website. Incanthera aims to develop solutions for unmet clinical needs, originating from the Institute of Cancer Therapeutics at the University of Bradford. For further inquiries, contact their team or visit their website for more information.
RNS Number : 6763D Incanthera PLC 16 October 2025
16 October 2025
Incanthera plc
("Incanthera" the "Company")
Investor Presentation
Proactive Investor Forum Presentation
Incanthera plc (AQSE:INC), the company specially focussed on innovative technologies in dermatology and oncology, advises that following their presentation at Proactive investor's One2One Biotech Investor Forum in London on 9 October 2025, the recording of the company's presentation is now available on the following link:
https://www.youtube.com/embed/mMnfpaj1ZCE?si=pikzFDks4YpOQ_En
This is also available to view on the Company's website, along with the investor presentation, given on the evening, at https://www.incanthera.com/investors/results-reports-and-presentations/.
RNS Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature.
For further enquiries:
Incanthera plc:
www.incanthera.com http://www.incanthera.com/ Tim McCarthy, Chairman tim.mccarthy@incanthera.com Simon Ward, Chief Executive Officer simon.ward@incanthera.com Suzanne Brocks, Head of Communications suzanne.brocks@incanthera.com | +44 (0) 7831 675747 +44 (0) 7747 625506 +44 (0) 7776 234600 |
Broker: Stanford Capital Partners Ltd Patrick Claridge / Bob Pountney | +44 (0) 20 3650 3650/51 |
Notes to Editors
Incanthera is a specialist company focused on innovative technologies in dermatology and oncology. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading specialists and academic institutions as well as its in-house development team.
The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford. Incanthera's strategy is to develop each candidate in its portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.
For more information on the Company please visit: www.incanthera.com
@incantheraplc
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END NRAUNRKRVBURARA
